Methotrexat Accord

Methotrexate, the active ingredient in Methotrexat Accord, is an antimetabolite presented as a sterile injectable for intraarterial, intramuscular and intrathecal use. It is employed in the management of rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and breast cancer in appropriate patients.

GNH USA supplies Methotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is an antimetabolite used across autoimmune and oncologic disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: inhibits malignant lymphoblast proliferation. - Non‑Hodgkin lymphoma: impedes tumor growth. - Breast cancer: part of combination regimens to limit tumor cell replication.

Methotrexate may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring early in therapy. - Mucositis: inflammation of the oral mucosa causing soreness. - Fatigue: general tiredness and reduced energy. - Mild liver enzyme elevation: transient increase in ALT/AST.

Serious or Rare Side Effects: - Bone marrow suppression: leading to anemia, leukopenia or thrombocytopenia. - Severe hepatotoxicity: marked liver enzyme rise or fibrosis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Cutaneous reactions: severe rash or Stevens‑Johnson syndrome.

Methotrexat Accord requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X) – avoid use in pregnant patients. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: monitor liver enzymes regularly to detect toxicity. - Hematology: perform complete blood counts to watch for bone‑marrow suppression. - Concomitant nephrotoxic drugs: avoid or adjust dose when used together. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexat Accord interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - NSAIDs: may increase methotrexate toxicity by reducing renal clearance. - Penicillins (e.g., ampicillin): can raise serum methotrexate levels. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Warfarin: enhanced anticoagulant effect; monitor INR. - Sulfasalazine: may increase hepatotoxic risk.